Maria Gavriatopoulou

Suggest Changes
Learn More
Magnetic Resonance Imaging (MRI) and specific cytogenetic abnormalities offer important prognostic information for myeloma patients. However, limited data are available about the association between(More)
Bone disease is a major complication of multiple myeloma (MM) [1]. Bortezomib is the first-in-class proteasome inhibitor, with established anti-myeloma activity and beneficial effect on bone(More)
OBJECTIVES Lenalidomide and dexamethasone (LenDex) is an active regimen for relapsed/refractory multiple myeloma (MM). However, there is limited data for the effect of LenDex on renal impairment (RI)(More)
We prospectively studied the impact of several cytogenetic abnormalities (CAs) in patients with relapsed/refractory myeloma who received lenalidomide and dexamethasone (RD) with or without the(More)